g(m3)-ganglioside and caffeic-acid-phenethyl-ester

g(m3)-ganglioside has been researched along with caffeic-acid-phenethyl-ester* in 1 studies

Other Studies

1 other study(ies) available for g(m3)-ganglioside and caffeic-acid-phenethyl-ester

ArticleYear
Ganglioside GM3 is required for caffeic acid phenethyl ester-induced megakaryocytic differentiation of human chronic myelogenous leukemia K562 cells.
    Biochemistry and cell biology = Biochimie et biologie cellulaire, 2014, Volume: 92, Issue:4

    The human chronic myelogenous cell line K562 has been used extensively as a model for the study of leukemia differentiation. We show here that treatment of K562 cells with caffeic acid phenethyl ester (CAPE) induced a majority of cells to differentiate towards the megakaryocytic lineage. Microscopy analysis showed that K562 cells treated with CAPE exhibited characteristic features of physiological megakaryocytic differentiation, including the presence of vacuoles and demarcation membranes. Differentiation of K562 cells treated with CAPE was also accompanied by a net increase in megakaryocytic markers. The transcriptional activity of lactosylceramide α-2,3-sialyltransferase (GM3 synthase) and synthesis of ganglioside GM3 were increased by CAPE treatment. The promoter analysis of GM3 synthase demonstrated that CAPE induced the expression of GM3 synthase mRNA via activation of the cAMP response element-binding protein (CREB), transcription factor in nucleus. Interestingly, the inhibition of ganglioside GM3 synthesis by D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propranol (D-PDMP) and GM3 synthase-siRNA blocked the CAPE-induced expression of the megakaryocytic markers and differentiation of K562 cells. Taken together, these results suggest that CAPE induces ganglioside GM3-mediated megakaryocytic differentiation of human chronic myelogenous cells.

    Topics: Antioxidants; Caffeic Acids; Cell Differentiation; Cell Proliferation; G(M3) Ganglioside; Humans; K562 Cells; Megakaryocytes; Phenylethyl Alcohol

2014